|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PCBD1 |
Gene summary for PCBD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PCBD1 | Gene ID | 5092 |
| Gene name | pterin-4 alpha-carbinolamine dehydratase 1 | |
| Gene Alias | DCOH | |
| Cytomap | 10q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006066 | UniProtAcc | P61457 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5092 | PCBD1 | GSM4909285 | Human | Breast | IDC | 1.35e-07 | 2.57e-01 | 0.21 |
| 5092 | PCBD1 | GSM4909291 | Human | Breast | IDC | 1.37e-03 | 3.58e-01 | 0.1753 |
| 5092 | PCBD1 | GSM4909293 | Human | Breast | IDC | 5.98e-80 | 1.02e+00 | 0.1581 |
| 5092 | PCBD1 | GSM4909296 | Human | Breast | IDC | 1.98e-32 | 6.15e-01 | 0.1524 |
| 5092 | PCBD1 | GSM4909297 | Human | Breast | IDC | 1.38e-09 | -1.74e-01 | 0.1517 |
| 5092 | PCBD1 | GSM4909302 | Human | Breast | IDC | 3.00e-03 | 2.27e-01 | 0.1545 |
| 5092 | PCBD1 | GSM4909304 | Human | Breast | IDC | 3.42e-05 | 3.39e-01 | 0.1636 |
| 5092 | PCBD1 | GSM4909306 | Human | Breast | IDC | 4.32e-09 | 4.11e-01 | 0.1564 |
| 5092 | PCBD1 | GSM4909308 | Human | Breast | IDC | 7.28e-16 | 4.88e-01 | 0.158 |
| 5092 | PCBD1 | GSM4909311 | Human | Breast | IDC | 4.72e-27 | 4.37e-02 | 0.1534 |
| 5092 | PCBD1 | GSM4909312 | Human | Breast | IDC | 1.41e-11 | 2.62e-01 | 0.1552 |
| 5092 | PCBD1 | GSM4909313 | Human | Breast | IDC | 9.48e-05 | 1.96e-01 | 0.0391 |
| 5092 | PCBD1 | GSM4909315 | Human | Breast | IDC | 3.09e-05 | 3.77e-01 | 0.21 |
| 5092 | PCBD1 | GSM4909316 | Human | Breast | IDC | 5.61e-11 | 5.09e-01 | 0.21 |
| 5092 | PCBD1 | GSM4909319 | Human | Breast | IDC | 4.91e-40 | 2.08e-02 | 0.1563 |
| 5092 | PCBD1 | GSM4909321 | Human | Breast | IDC | 1.07e-14 | 2.45e-01 | 0.1559 |
| 5092 | PCBD1 | brca2 | Human | Breast | Precancer | 4.86e-03 | 6.29e-02 | -0.024 |
| 5092 | PCBD1 | M2 | Human | Breast | IDC | 7.44e-03 | 1.70e-01 | 0.21 |
| 5092 | PCBD1 | M5 | Human | Breast | IDC | 8.24e-05 | 5.15e-01 | 0.1598 |
| 5092 | PCBD1 | NCCBC14 | Human | Breast | DCIS | 4.91e-09 | -1.03e-01 | 0.2021 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00425594 | Oral cavity | OSCC | pteridine-containing compound biosynthetic process | 13/7305 | 15/18723 | 2.07e-04 | 1.36e-03 | 13 |
| GO:19016173 | Oral cavity | OSCC | organic hydroxy compound biosynthetic process | 115/7305 | 237/18723 | 1.73e-03 | 8.18e-03 | 115 |
| GO:00086524 | Oral cavity | OSCC | cellular amino acid biosynthetic process | 42/7305 | 76/18723 | 2.93e-03 | 1.27e-02 | 42 |
| GO:19016074 | Oral cavity | OSCC | alpha-amino acid biosynthetic process | 37/7305 | 68/18723 | 7.09e-03 | 2.63e-02 | 37 |
| GO:00425583 | Oral cavity | OSCC | pteridine-containing compound metabolic process | 20/7305 | 33/18723 | 9.78e-03 | 3.45e-02 | 20 |
| GO:0051098110 | Oral cavity | LP | regulation of binding | 140/4623 | 363/18723 | 2.47e-09 | 1.10e-07 | 140 |
| GO:004339319 | Oral cavity | LP | regulation of protein binding | 80/4623 | 196/18723 | 4.41e-07 | 1.23e-05 | 80 |
| GO:190160711 | Oral cavity | LP | alpha-amino acid biosynthetic process | 28/4623 | 68/18723 | 2.01e-03 | 1.49e-02 | 28 |
| GO:000606613 | Oral cavity | LP | alcohol metabolic process | 111/4623 | 353/18723 | 2.24e-03 | 1.62e-02 | 111 |
| GO:000865211 | Oral cavity | LP | cellular amino acid biosynthetic process | 30/4623 | 76/18723 | 3.07e-03 | 2.09e-02 | 30 |
| GO:004255912 | Oral cavity | LP | pteridine-containing compound biosynthetic process | 9/4623 | 15/18723 | 3.82e-03 | 2.48e-02 | 9 |
| GO:005109818 | Prostate | BPH | regulation of binding | 121/3107 | 363/18723 | 2.74e-15 | 4.14e-13 | 121 |
| GO:004339316 | Prostate | BPH | regulation of protein binding | 60/3107 | 196/18723 | 7.72e-07 | 1.45e-05 | 60 |
| GO:005109819 | Prostate | Tumor | regulation of binding | 122/3246 | 363/18723 | 2.86e-14 | 3.63e-12 | 122 |
| GO:004339317 | Prostate | Tumor | regulation of protein binding | 60/3246 | 196/18723 | 3.36e-06 | 5.45e-05 | 60 |
| GO:005109827 | Skin | cSCC | regulation of binding | 152/4864 | 363/18723 | 2.21e-11 | 1.10e-09 | 152 |
| GO:004339325 | Skin | cSCC | regulation of protein binding | 79/4864 | 196/18723 | 7.59e-06 | 1.04e-04 | 79 |
| GO:19016076 | Skin | cSCC | alpha-amino acid biosynthetic process | 30/4864 | 68/18723 | 8.91e-04 | 6.10e-03 | 30 |
| GO:00425596 | Skin | cSCC | pteridine-containing compound biosynthetic process | 10/4864 | 15/18723 | 1.10e-03 | 7.24e-03 | 10 |
| GO:00425585 | Skin | cSCC | pteridine-containing compound metabolic process | 16/4864 | 33/18723 | 4.50e-03 | 2.30e-02 | 16 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PCBD1 | insertion | Frame_Shift_Ins | novel | c.276_277insTCCTTGCTGTGGGATGTGCCAGTGTCCCC | p.Ala93SerfsTer17 | p.A93Sfs*17 | P61457 | protein_coding | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PCBD1 | SNV | Missense_Mutation | novel | c.280N>G | p.Ser94Gly | p.S94G | P61457 | protein_coding | tolerated(0.12) | benign(0.106) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCBD1 | SNV | Missense_Mutation | novel | c.89N>T | p.Gly30Val | p.G30V | P61457 | protein_coding | deleterious(0) | possibly_damaging(0.846) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PCBD1 | SNV | Missense_Mutation | rs368664467 | c.250G>A | p.Gly84Ser | p.G84S | P61457 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A5-A0GQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCBD1 | SNV | Missense_Mutation | rs11554325 | c.91N>T | p.Arg31Cys | p.R31C | P61457 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PCBD1 | SNV | Missense_Mutation | novel | c.224T>C | p.Ile75Thr | p.I75T | P61457 | protein_coding | deleterious(0.03) | probably_damaging(0.989) | TCGA-B5-A11O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| PCBD1 | SNV | Missense_Mutation | novel | c.65C>A | p.Ala22Asp | p.A22D | P61457 | protein_coding | tolerated(0.3) | benign(0.007) | TCGA-R5-A7ZI-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5092 | PCBD1 | ENZYME | H2O2 | 14530988 | ||
| 5092 | PCBD1 | ENZYME | ANTISERUM | 10403117 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |